Acadian Asset Management
RYTM icon

Acadian Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Acadian Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$192K Sell
2,218
-3,887
-64% -$378K ﹤0.01% 1601
2025
Q4 		$652K Buy
+6,105
New +$648K ﹤0.01% 1235
2024
Q4 		– Sell
-4,858
Closed -$254K – 2089
2024
Q3 		$254K Buy
+4,858
New +$233K ﹤0.01% 1282

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Acadian Asset Management's RYTM Position: Q1 2026 in Review

Acadian Asset Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 64% in Q1 2026, selling an estimated $378K and leaving 2,218 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #1601.

Acadian Asset Management first reported a position in RYTM in Q3 2024 and has held it in 3 quarters since. The position peaked at $652K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Acadian Asset Management held 2,218 shares of Rhythm Pharmaceuticals worth $192K as of Q1 2026.
  • Acadian Asset Management sold 3,887 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $378K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1601 holding.
  • Acadian Asset Management first reported a position in Rhythm Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • Acadian Asset Management's Rhythm Pharmaceuticals position peaked at $652K in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.